Maze Therapeutics, Inc. (MAZE)

US — Healthcare Sector
Peers: ZYME  ARDX  PHVS  BCRX  IMNM  SYRE  SION  NTLA  WVE  TRVI 

Automate Your Wheel Strategy on MAZE

With Tiblio's Option Bot, you can configure your own wheel strategy including MAZE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

News

Maze Therapeutics: MZE829 Presses Forward Despite Stock Price Drop
MAZE
Published: March 27, 2026 by: Seeking Alpha
Sentiment: Neutral

I am initiating coverage on Maze Therapeutics (MAZE) with a "Buy" rating following positive phase 2 HORIZON data for MZE829 in APOL1-mediated kidney disease. MZE829 achieved a 35.6% mean reduction in proteinuria, exceeding the ≥30% uACR threshold required for clinical relevance and potential regulatory advancement. Despite a 37% stock drop post-data, I view the market reaction as overblown given the program's success and planned pivotal trial initiation.

Read More
image for news Maze Therapeutics: MZE829 Presses Forward Despite Stock Price Drop
After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Maze Therapeutics, Inc. (MAZE)
MAZE
Published: March 27, 2026 by: Zacks Investment Research
Sentiment: Negative

The heavy selling pressure might have exhausted for Maze Therapeutics, Inc. (MAZE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Read More
image for news After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Maze Therapeutics, Inc. (MAZE)
Maze Therapeutics, Inc. (MAZE) Presents at Jefferies London Healthcare Conference 2025 Prepared Remarks Transcript
MAZE
Published: November 25, 2025 by: Seeking Alpha
Sentiment: Neutral

Maze Therapeutics, Inc. ( MAZE ) Jefferies London Healthcare Conference 2025 November 20, 2025 7:00 AM EST Company Participants Jason Coloma - CEO & Director Presentation Jason Coloma CEO & Director Good morning, everyone. I'm Jason Coloma.

Read More
image for news Maze Therapeutics, Inc. (MAZE) Presents at Jefferies London Healthcare Conference 2025 Prepared Remarks Transcript
National Advertising Division Refers Maze Therapeutics to Regulatory Authorities for Failure to Respond to Inquiry
MAZE
Published: August 27, 2025 by: GlobeNewsWire
Sentiment: Neutral

Following a challenge brought by Vertex Pharmaceuticals Incorporated, BBB National Programs' National Advertising Division will refer claims made by Maze Therapeutics, Inc. to the appropriate regulatory authorities for review and possible enforcement action for failure to submit a substantive response to the National Advertising Division's (NAD) inquiry. Following a challenge brought by Vertex Pharmaceuticals Incorporated, BBB National Programs' National Advertising Division will refer claims made by Maze Therapeutics, Inc. to the appropriate regulatory authorities for review and possible enforcement action for failure to submit a substantive response to the National Advertising Division's (NAD) inquiry.

Read More
image for news National Advertising Division Refers Maze Therapeutics to Regulatory Authorities for Failure to Respond to Inquiry

About Maze Therapeutics, Inc. (MAZE)

  • IPO Date 2025-01-31
  • Website https://www.mazetx.com
  • Industry Biotechnology
  • CEO Jason V. Coloma
  • Employees 125
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs includes MZE829, an oral small molecule inhibitor of apolipoprotein L1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.